Changes in bioimpedance by age. by Domingos L. S. Rios (20496173)

“…Methods: This study was a retrospective cohort comparing exposure variables in a secondary data analysis with a pre-post treatment design. …”

S1 Data - by Domingos L. S. Rios (20496173)

“…Methods: This study was a retrospective cohort comparing exposure variables in a secondary data analysis with a pre-post treatment design. …”

Comparison of demographic features. by Yueju Cai (20978633)

“…Additionally, a decrease in birth weight was significantly linked to an increased risk of readmission (OR = 0.998, P = 0.013), although the effect size was relatively small.…”

Data. by Yueju Cai (20978633)

“…Additionally, a decrease in birth weight was significantly linked to an increased risk of readmission (OR = 0.998, P = 0.013), although the effect size was relatively small.…”

Comparison of examination test and treatment. by Yueju Cai (20978633)

“…Additionally, a decrease in birth weight was significantly linked to an increased risk of readmission (OR = 0.998, P = 0.013), although the effect size was relatively small.…”

Specifications of prototypes of RSSCA system. by Ngoc-Hai Vu (22290844)

“…Compared to conventional PV systems, the RSSCA offers improved light uniformity, better land-use efficiency, and significantly higher electricity generation. However, in regions with limited direct sunlight, such as Seoul in winter, system performance decreases. …”

Software testing process flowchart. by Mohammadreza Namdar (22439057)

“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”

The ROC of LR for three classes. by Mohammadreza Namdar (22439057)

“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”

The ROC of MNB for three classes. by Mohammadreza Namdar (22439057)

“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”

Problem solution process model. by Mohammadreza Namdar (22439057)

“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”

The ROC of SVM for three classes. by Mohammadreza Namdar (22439057)

“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”

The ROC of RF for three classes. by Mohammadreza Namdar (22439057)

“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”

The ROC of GNB for three classes. by Mohammadreza Namdar (22439057)

“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”

The accuracy of classifiers and voting plans. by Mohammadreza Namdar (22439057)

“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”

Metrics formula [24]. by Mohammadreza Namdar (22439057)

“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”

A protein-protein interaction (PPI) map of the paclitaxel associated DRG proteome. by Rania Hanna (18830411)

Baseline characteristics of participants. by Hyungjong Park (10147327)

“…In the multivariable Cox regression analysis, eGFR > 120 mL/min ∙ 1.73 m² was associated with a decreased risk of dyslipidemia (HR: 0.35; 95% CI [0.34–0.36]). …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”